Avanos Medical (AVNS) Proxy filing summary

Executive summary

• All regulatory approvals for the acquisition by AIP affiliates have been received as of July 2, 2026, enabling the transaction to proceed to closing pending shareholder approval and customary conditions.

• The special meeting for stockholder approval is scheduled for July 22, 2026, with the transaction expected to close by July 27, 2026.

• Forward-looking statements highlight anticipated benefits of the merger, including innovation and growth, but also note risks such as potential competing proposals and impacts on relationships with stakeholders.

Voting matters and shareholder proposals

• Stockholders are being asked to approve the proposed acquisition at a special meeting.

• Proxy materials and voting instructions are available online and through the company's investor relations.

Board of directors and corporate governance

• Directors, executive officers, and employees may be considered participants in the proxy solicitation for the merger.

• Information on beneficial ownership by directors and officers is disclosed in SEC filings and referenced in the proxy statement.